Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck Receives Positive CHMP Opinion For Januvia, Janumet
Merck & Co. has received a positive opinion from the EMEA’s Committee for Medicinal Products for Human Use (CHMP) for Januvia tablets and Janumet tablets recommending their use
Merck & Co. has received a positive opinion from the EMEA’s Committee for Medicinal Products for Human Use (CHMP) for Januvia tablets and Janumet tablets recommending their use
Focetria, the Novartis Influenza A(H1N1) 2009 monovalent vaccine, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA. Reportedly, the
The FDA has granted accelerated approval for Allos Therapeutics’ FOLOTYN(pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell
Bioniche Pharma and Synerx Pharma, have launch of Fomepizole Injection, which is the generic equivalent of Paladin Labs’ Antizol. George Zorich, president for US Operations at Bioniche Pharma,
The Drugs Controller General of India (DCGI) has issued guidelines for grant of WHO-GMP Certificate of Pharmaceutical Product (CoPP) by the CDSCO offices, starting October 1. DCGI has
NicOx has announced that a New Drug Application (NDA) for naproxcinod has been submitted to the FDA, seeking approval for an indication for the relief of the signs
Active Biotech’s prostate cancer project TASQ, where TASQ was studied as a single agent in patients with castration-resistant prostate cancer, was published in British Journal of Cancer. Two
The new data from the phase III PLATO study showed that AstraZeneca’s BRILINTA (ticagrelor) provided reduction of cardiovascular (CV) events than clopidogrel (9.02% vs 10.65%, p=0.0025 a 16%
Aesica’s Cramlington, UK site has been recently granted a Home Office licence to allow manufacture and supply of substances listed in Schedule 2 of the Misuse of Drugs
“Just weeks ago we received clearance from the US Treasury Department to extend our US clinical program for nimotuzumab, permitting us to conduct trials in any cancer indication.